CY1120199T1 - Σκευασμα αερολυματος για την εισπνοη βητα αγωνιστων - Google Patents

Σκευασμα αερολυματος για την εισπνοη βητα αγωνιστων

Info

Publication number
CY1120199T1
CY1120199T1 CY20181100484T CY181100484T CY1120199T1 CY 1120199 T1 CY1120199 T1 CY 1120199T1 CY 20181100484 T CY20181100484 T CY 20181100484T CY 181100484 T CY181100484 T CY 181100484T CY 1120199 T1 CY1120199 T1 CY 1120199T1
Authority
CY
Cyprus
Prior art keywords
inhalation
agonor
aerospol
beta
preparation
Prior art date
Application number
CY20181100484T
Other languages
English (en)
Inventor
Barbara Niklaus-Humke
Michael Nowak
Kirsten Radau
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1120199T1 publication Critical patent/CY1120199T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ένα σκεύασμα αερολύματος χωρίς προωθητικό αέριο για εισπνοή, το οποίο περιέχει μία ή περισσότερες ενώσεις του γενικού τύπου (1), στον οποίο οι ρίζες R1, R2, R3 και Χˉ μπορούν να έχουν τις σημασίες που αναφέρονται στις αξιώσεις και στην περιγραφή, και μία περαιτέρω δραστική ουσία 2.
CY20181100484T 2005-10-10 2018-05-10 Σκευασμα αερολυματος για την εισπνοη βητα αγωνιστων CY1120199T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10
PCT/EP2006/067126 WO2007042468A2 (de) 2005-10-10 2006-10-06 Aerosolformulierung für die inhalation von betaagonisten
EP06807028.3A EP1940349B1 (de) 2005-10-10 2006-10-06 Aerosolformulierung für die inhalation von betaagonisten

Publications (1)

Publication Number Publication Date
CY1120199T1 true CY1120199T1 (el) 2018-12-12

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100484T CY1120199T1 (el) 2005-10-10 2018-05-10 Σκευασμα αερολυματος για την εισπνοη βητα αγωνιστων

Country Status (31)

Country Link
US (3) US20070088030A1 (el)
EP (1) EP1940349B1 (el)
JP (1) JP2009511542A (el)
KR (1) KR20080059290A (el)
CN (1) CN101282712A (el)
AR (1) AR058082A1 (el)
AU (1) AU2006301330B9 (el)
BR (1) BRPI0617278A2 (el)
CA (1) CA2624786C (el)
CY (1) CY1120199T1 (el)
DK (1) DK1940349T3 (el)
EA (1) EA200800927A1 (el)
EC (1) ECSP088294A (el)
ES (1) ES2668364T3 (el)
HR (1) HRP20180713T1 (el)
HU (1) HUE039186T2 (el)
IL (1) IL190682A (el)
LT (1) LT1940349T (el)
MY (1) MY163503A (el)
NO (1) NO343363B1 (el)
NZ (1) NZ567545A (el)
PE (1) PE20070708A1 (el)
PL (1) PL1940349T3 (el)
PT (1) PT1940349T (el)
RS (1) RS57085B1 (el)
SI (1) SI1940349T1 (el)
TW (1) TWI389692B (el)
UA (1) UA99250C2 (el)
UY (1) UY29844A1 (el)
WO (1) WO2007042468A2 (el)
ZA (1) ZA200801390B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
RU2412176C2 (ru) * 2005-08-15 2011-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения бетамиметиков
JP2012509298A (ja) * 2008-11-21 2012-04-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング β作用薬吸入用のエアロゾル製剤
CA2738617A1 (en) * 2008-11-21 2011-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR20180042160A (ko) * 2015-05-18 2018-04-25 글렌마크 스페셜티 에스. 에이. 분무용 티오트로피움 흡입 용액
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
US20210322311A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
AU680227B2 (en) * 1992-12-09 1997-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
EA200201056A1 (ru) * 2000-04-27 2003-04-24 Бёрингер Ингельхайм Фарма Кг Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
BRPI0510080B8 (pt) * 2004-04-22 2021-05-25 Boehringer Ingelheim Int combinação farmacêutica e seu uso
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

Also Published As

Publication number Publication date
EP1940349B1 (de) 2018-02-14
EA200800927A1 (ru) 2008-10-30
TWI389692B (zh) 2013-03-21
CN101282712A (zh) 2008-10-08
US20110190284A1 (en) 2011-08-04
CA2624786A1 (en) 2007-04-19
WO2007042468A3 (de) 2007-08-02
NO20080801L (no) 2008-04-29
PE20070708A1 (es) 2007-08-06
LT1940349T (lt) 2018-05-10
RS57085B1 (sr) 2018-06-29
BRPI0617278A2 (pt) 2011-07-19
JP2009511542A (ja) 2009-03-19
AU2006301330B9 (en) 2013-01-17
AU2006301330A1 (en) 2007-04-19
ECSP088294A (es) 2008-04-28
UY29844A1 (es) 2007-05-31
HUE039186T2 (hu) 2018-12-28
IL190682A (en) 2015-06-30
UA99250C2 (ru) 2012-08-10
US20100009984A1 (en) 2010-01-14
ZA200801390B (en) 2009-01-28
SI1940349T1 (en) 2018-05-31
AU2006301330B2 (en) 2012-11-22
AR058082A1 (es) 2008-01-23
WO2007042468A2 (de) 2007-04-19
KR20080059290A (ko) 2008-06-26
NO343363B1 (no) 2019-02-11
CA2624786C (en) 2015-06-16
TW200730178A (en) 2007-08-16
EP1940349A2 (de) 2008-07-09
PL1940349T3 (pl) 2018-07-31
IL190682A0 (en) 2008-11-03
PT1940349T (pt) 2018-04-30
ES2668364T3 (es) 2018-05-17
MY163503A (en) 2017-09-15
HRP20180713T1 (hr) 2018-06-15
US20070088030A1 (en) 2007-04-19
NZ567545A (en) 2011-07-29
DK1940349T3 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
CY1120199T1 (el) Σκευασμα αερολυματος για την εισπνοη βητα αγωνιστων
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
ATE433447T1 (de) Pyrimiidinverbindungen
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1114095T1 (el) Μυκητοκτονες συνθεσεις
SE0301700D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
NO20041493L (no) Kjemiske forbindelser.
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
ATE365740T1 (de) Substituierte pyrazolopyrimidine
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
ECSP067004A (es) Formulación en aerosol para la inhalación de beta-agonistas
AR062425A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
NO20092271L (no) Metoder og formuleringer for forbedret biotilgjengelighet av antiprogestiner
CY1118146T1 (el) Σταθερες σε αποθηκευση φαρμακοτεχνικες μορφες σουλφοναμιδιων
CY1111983T1 (el) Φαρμακευτικη συνθεση και μεθοδος χρησης αντιμυκητιακου παραγοντα σε συνδυασμο
NO20054535L (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
PA8582101A1 (es) Indoles sustituidos en posicion 2,4